<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836483</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-15-2-01</org_study_id>
    <nct_id>NCT02836483</nct_id>
  </id_info>
  <brief_title>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</brief_title>
  <official_title>A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II
      Trial of LCB01-0371.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to explore antituberculosis of LCB01-0371 through the assess of the
      early bactericidal activity, safety of administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EBA0-14</measure>
    <time_frame>V2(Baseline, Day 1), V9(Day 15)</time_frame>
    <description>The extended early bactericidal activity (extended EBA) expressed as the change of log colony forming units of sputum from baseline at Day 15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EBA0-2</measure>
    <time_frame>V2(Baseline, Day 1), V4(Day 3)</time_frame>
    <description>The standard early bactericidal activity (standard EBA) expressed as the change of log colony forming units of sputum from baseline at Day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBA2-14</measure>
    <time_frame>V4(Day 3), V9(Day 15)</time_frame>
    <description>The extended early bactericidal activity (extended EBA) expressed as the change of log colony forming units of sputum from Day 3 at Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBA2-7</measure>
    <time_frame>V4(Day 3), V6(Day 8)</time_frame>
    <description>The extended early bactericidal activity (extended EBA) expressed as the change of log colony forming units of sputum from Day 2 at Day 8</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 800mg, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 400mg, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 800mg, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tubes 3~5Tablet, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zyvox 600mg, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 800mg, QD</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>LCB01-0371</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 400mg, BID</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>LCB01-0371</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 800mg, BID</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>LCB01-0371</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tubes 3~5Tablet, QD</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Tubes Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zyvox 600mg, BID</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>Zyvox Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Korean who After listening to understand the details about the clinical trial, decided
             to join in the clinical study, and written consent

          2. The age of consent at the time of writing, only men and women under 70 years old over
             19 years old

          3. The First diagnosis of tuberculosis and have not received tuberculosis treatment for
             TB patients

        Exclusion Criteria:

          1. Known history of Rifampicin or Isoniazid resistance

          2. Serious TB for example tuberculous encephalomeningitis, It is impossible to
             participate in clinical trials

          3. Known History of nontuberculous mycobacteria positive

          4. Other pulmonary disease which is impossible to participate in clinical trial except TB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T.S Sim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>T.S. Sim, M.D., Ph.D</last_name>
    <phone>82-2-3010-3892</phone>
    <email>shimts@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T.S. Sim, M.D., Ph.D</last_name>
      <phone>82-2-3010-3892</phone>
      <email>shimts@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

